Diez M, Torres A, Ortega L, Maestro M, Hernando F, Gomez A, Picardo A, Granell J, Balibrea J L
General Surgery, University Hospital Principe de Asturias, Alcala de Henares, Spain.
Oncology. 1993 Mar-Apr;50(2):127-31. doi: 10.1159/000227163.
To assess the prognostic value of pretreatment serum neuron-specific enolase (NSE) in nonsmall cell lung cancer (NSCLC), levels were measured in 84 NSCLC patients, 40 healthy controls, and 20 patients with benign pulmonary diseases. NSE concentration was higher in NSCLC (11.7 +/- 10.8 ng/ml) (mean +/- SD; median = 9.7 ng/ml) than in the two control groups (p < 0.001). Serum NSE was neither related with the tumor-node-metastasis (TNM) stage, nor with histologic subtype. At a cutoff value of 15 ng/ml, NSE had a sensitivity of 27.3% and a specificity of 96%. Patients with a preoperative NSE level < 15 ng/ml showed significantly longer 24-month survival than those whose initial levels were > 15 ng/ml (70 vs, 47%; p < 0.05), and this was confirmed after stratifying by TNM stage. Likelihood of tumor relapse in I, II, and IIIa TNM stages showed similar behavior. These findings suggest that NSE could be used as an adjunctive prognostic test in NSCLC patients.
为评估治疗前血清神经元特异性烯醇化酶（NSE）在非小细胞肺癌（NSCLC）中的预后价值，对84例NSCLC患者、40例健康对照者以及20例良性肺部疾病患者进行了NSE水平检测。NSCLC患者的NSE浓度（11.7±10.8 ng/ml）（均值±标准差；中位数=9.7 ng/ml）高于两个对照组（p<0.001）。血清NSE与肿瘤-淋巴结-转移（TNM）分期及组织学亚型均无关。NSE临界值为15 ng/ml时，其敏感性为27.3%，特异性为96%。术前NSE水平<15 ng/ml的患者24个月生存率显著高于初始水平>15 ng/ml的患者（70%对47%；p<0.05），按TNM分期分层后也得到证实。TNM I、II和IIIa期肿瘤复发的可能性表现相似。这些结果表明，NSE可作为NSCLC患者的辅助预后检测指标。
